Commit Biologics, a Danish biotech developing complement-powered immune engagers, said Nov. 17 that it has closed a $60 million (€54 million) seed financing backed by AbbVie Ventures, M Ventures and Ackermans & van Haaren. The money is meant to carry its lead program, COM002, into first human trials.
Existing investors Bioqube Ventures, Korys and Novo Holdings also took part, according to the company's announcement.
What the round does and doesn't add up to
The Nov. 17 announcement described a final close. European Biotechnology reported the same day that it brings accumulated seed financing to $60 million, which means the €54 million should not be stacked on top of earlier seed money. Commit's two previous seed announcements were a €16 million launch round in May 2024 and a €5.5 million extension from Korys in January 2025, together the €21.5 million it had already disclosed.
CEO Thomas L. F. Montgomery Andresen told BioXconomy on Nov. 18 that the round was oversubscribed. Commit disclosed no valuation.
One figure needs care. Ackermans & van Haaren's own release described a conditional commitment of up to €10.5 million, paid in tranches. That is a ceiling, not cash already in Commit's account.
Fierce Biotech has listed Commit in its 2026 fundraising tracker, which covers rounds of $50 million or more.
Where the money is going

COM002 is the first development candidate to emerge from BiCE, Commit's platform for engaging the complement system, a part of the immune system that helps clear threats. The company nominated it on Nov. 12 and, the same day, appointed Dr. Benjamin Ole Wolthers as head of clinical development.
According to the release, COM002 targets a B-cell antigen. Ackermans & van Haaren's release said the drug is intended to deplete B cells and follicular helper T cells. Commit announced on Nov. 11, 2025, that it had shown proof of concept for the platform in non-human primates. That is preclinical evidence, and it says little yet about whether patients will benefit.
Proceeds will also support a second program, which the announcement did not name.
Who is at the table
Commit's people page lists Michael Rosenzweig of AbbVie Ventures, Charlotte Kremers of M Ventures and Lenny Van Steenhuyse of Ackermans & van Haaren on its board, alongside chair Anker Lundemose. M Ventures describes itself as the corporate venture fund of Merck KGaA, Darmstadt, Germany. AbbVie Ventures, in its 2025 impact report, describes an "invest-to-partner" approach. Neither investment amounts to a licensing deal or partnership, and nothing in the announcement suggests one is pending.
Novo Holdings said in a LinkedIn update that it became Commit's first institutional investor after early support from BII. The company's release says the concept came from four Aarhus scientists who developed it alongside their regular research roles.
A crowded field in autoimmune disease
Commit's pipeline page lists immune thrombocytopenia and rheumatoid arthritis. Those are the same autoimmune indications Janux Therapeutics plans to prioritize for JANX011, which reported initial Phase 1 healthy-volunteer data on Nov. 9. The two approaches differ: JANX011 recruits a defined T-cell subset rather than complement, so no cross-trial comparison is justified.
Big pharma is also paying for T-cell engagers in autoimmunity. Sanofi's first-half 2026 filing records a March 2026 worldwide license for Kali Therapeutics' trispecific T-cell engager KT501. Disclosed economics run up to $1.2 billion, with $100 million paid by June 30, 2026.
What comes next

COM002 has not yet been dosed in humans. Commit has pointed to first-in-human trials as the next step, and this seed round is meant to pay for getting there.
